雷戈拉菲尼布诱导了一名耐火性直肠癌患者的间歇性肺炎
Tomo Tsunoda1, Yoshiyuki Oyama1, Ryota Miyamoto1
1Department of Respiratory Medicine Shizuoka Saiseikai General Hospital Shizuoka Japan.
Respirology case reports
|August 1, 2025
概括
癌症药物雷戈拉费尼布 (Regorafenib) 可能导致间歇性肺病,这是一个严重的副作用. 这一案例凸显了早期检测和干预这种肺毒性的重要性.
科学领域:
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 雷戈拉菲尼布是一种多向的氨酸激酶抑制剂 (TKI),用于耐火性结直肠癌,胃肠道瘤 (GIST) 和肝细胞癌 (HCC).
- 肺毒性,包括间歇性肺病 (ILD),是已知的,但可能未被认可的与TKI治疗相关的不良事件.
研究的目的:
- 在患有耐火性结肠直肠癌的患者中报告regorafenib治疗后发生的间歇性肺炎病例.
- 强调对调法尼布诱导的ILD所需的快速进展和临床警.
主要方法:
- 一个66岁的男性患者的病例报告,他因耐火性结直肠癌而接受了regorafenib治疗.
- 临床观察和胸部计算机断层扫描 (CT) 扫描结果记录了间歇性肺部疾病的发展.
主要成果:
- 患者在开始治疗regorafenib后三个月就出现了间歇性肺炎.
- 胸部CT显示双边地面玻璃不透明,表明ILD.
- 该病例表明药物诱导的肺部疾病的放射性表现和进展相对较快.
结论:
- 雷戈拉费尼布可以诱导间歇性肺病,即使有看似短暂的潜伏期.
- 临床医生必须在接受regorafenib的患者中保持高的肺毒性怀疑指数.
- 早期识别和及时管理对于改善雷戈拉费尼布诱导的ILD的结果至关重要.
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
254
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
254